Payment overview · 2025
General Payments
$2,176.17
90 reported records · 26 companies
Healthcare provider profile · identity verified
Richard I Wright, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RIVERDALE, GA · NPI 1770573552
Verified facts
What the public records show
CMS Open Payments records show Richard I Wright, MD received $2,176.17 in general payments during 2025 across 90 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 17.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Nurtec Odt, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 387 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 979 claims for Eliquis by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Biktarvy by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 979 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lantus by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $384.24 | 17.7% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $188.11 | 8.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $182.66 | 8.4% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $167.11 | 7.7% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $164.89 | 7.6% | 8 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $128.90 | 5.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $103.70 | 4.8% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $90.38 | 4.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.18 | 3.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $66.65 | 3.1% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $65.74 | 3.0% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $65.12 | 3.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $63.42 | 2.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $58.72 | 2.7% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.62 | 2.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $51.57 | 2.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.90 | 2.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.08 | 1.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.10 | 1.4% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $26.65 | 1.2% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $26.00 | 1.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $25.71 | 1.2% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $23.85 | 1.1% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $19.46 | 0.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.08 | 0.7% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $14.33 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,176.17 | 90 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $435.81 | 19 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $182.66 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $164.89 | 8 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $128.90 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $123.67 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $103.70 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $90.38 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $88.23 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $86.21 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $67.03 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $66.65 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $65.74 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $65.12 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $64.44 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $63.42 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $58.72 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $54.62 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $54.62 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $52.32 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $51.08 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.90 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.40 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.08 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.78 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.10 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $27.80 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $26.65 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $25.71 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 979 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 119 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 387 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 64 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 114 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 91 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
119 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
387 | 55 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
979 | 58 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
91 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
84 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
91 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
979 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2337 | 235 |
| Amlodipine Besylate | Amlodipine Besylate | 2126 | 218 |
| Donepezil Hcl | Donepezil Hcl | 1517 | 65 |
| Trazodone Hcl | Trazodone Hcl | 1165 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1119 | 103 |
| Metformin Hcl | Metformin Hcl | 1117 | 90 |
| Memantine Hcl | Memantine Hcl | 1068 | 48 |
| Sertraline Hcl | Sertraline Hcl | 1044 | 50 |
| Eliquis | Apixaban | 979 | 58 |
| Carvedilol | Carvedilol | 968 | 71 |
| Potassium Chloride | Potassium Chloride | 947 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 895 | 75 |
| Mirtazapine | Mirtazapine | 870 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 866 | 63 |
| Losartan Potassium | Losartan Potassium | 821 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 773 | 82 |
| Furosemide | Furosemide | 762 | 83 |
| Lisinopril | Lisinopril | 762 | 75 |
| Hydralazine Hcl | Hydralazine Hcl | 756 | 77 |
| Risperidone | Risperidone | 741 | 27 |
| Simvastatin | Simvastatin | 698 | 63 |
| Divalproex Sodium | Divalproex Sodium | 687 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 659 | 29 |
| Levetiracetam | Levetiracetam | 646 | 46 |
| Quetiapine Fumarate | Quetiapine Fumarate | 616 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 565 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 528 | 62 |
| Benztropine Mesylate | Benztropine Mesylate | 498 | 17 |
| Gabapentin | Gabapentin | 463 | 114 |
| Tramadol Hcl | Tramadol Hcl | 440 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 431 | 34 |
| Omeprazole | Omeprazole | 427 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 399 | 22 |
| Jardiance | Empagliflozin | 387 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 368 | 53 |
| Nifedipine Er | Nifedipine | 368 | 59 |
| Olanzapine | Olanzapine | 332 | 14 |
| Alprazolam | Alprazolam | 307 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 305 | 26 |
| Finasteride | Finasteride | 298 | 17 |
| Allopurinol | Allopurinol | 262 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 251 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 251 | 26 |
| Baclofen | Baclofen | 242 | 16 |
| Glipizide | Glipizide | 241 | 25 |
| Meloxicam | Meloxicam | 237 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 231 | 12 |
| Montelukast Sodium | Montelukast Sodium | 227 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 206 | 13 |
| Clonidine Hcl | Clonidine Hcl | 203 | 22 |
| Lorazepam | Lorazepam | 200 | 60 |
| Atenolol | Atenolol | 192 | 19 |
| Xarelto | Rivaroxaban | 190 | 17 |
| Buspirone Hcl | Buspirone Hcl | 188 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 176 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 173 | 16 |
| Sucralfate | Sucralfate | 171 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 168 | 20 |
| Midodrine Hcl | Midodrine Hcl | 167 | 11 |
| Prednisone | Prednisone | 167 | 26 |
| Januvia | Sitagliptin Phosphate | 155 | 16 |
| Glimepiride | Glimepiride | 150 | 11 |
| Torsemide | Torsemide | 149 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 147 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 146 | 22 |
| Propranolol Hcl | Propranolol Hcl | 146 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 141 | suppressed |
| Aripiprazole | Aripiprazole | 134 | suppressed |
| Latanoprost | Latanoprost | 132 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 48 |
| Haloperidol | Haloperidol | 124 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 124 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 119 | 11 |
| Amantadine | Amantadine Hcl | 116 | suppressed |
| Lamotrigine | Lamotrigine | 116 | suppressed |
| Ozempic | Semaglutide | 114 | 28 |
| Calcium Acetate | Calcium Acetate | 113 | suppressed |
| Mounjaro | Tirzepatide | 112 | 19 |
| Lithium Carbonate | Lithium Carbonate | 106 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 104 | suppressed |
| Methylprednisolone | Methylprednisolone | 100 | 74 |
| Myrbetriq | Mirabegron | 99 | 11 |
| Metformin Hcl Er | Metformin Hcl | 96 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 20 |
| Potassium Citrate Er | Potassium Citrate | 94 | suppressed |
| Cilostazol | Cilostazol | 93 | suppressed |
| Rexulti | Brexpiprazole | 91 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 86 | suppressed |
| Azithromycin | Azithromycin | 85 | 62 |
| Glycopyrrolate | Glycopyrrolate | 85 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 84 | suppressed |
| Topiramate | Topiramate | 84 | suppressed |
| Famotidine | Famotidine | 83 | 25 |
| Sevelamer Carbonate | Sevelamer Carbonate | 82 | suppressed |
| Spironolactone | Spironolactone | 82 | 11 |
| Digoxin | Digoxin | 77 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | suppressed |
| Ibuprofen | Ibuprofen | 74 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 72 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 70 | 17 |
| Clonazepam | Clonazepam | 70 | 18 |
| Pregabalin | Pregabalin | 70 | 19 |
| Venlafaxine Hcl | Venlafaxine Hcl | 70 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 68 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 68 | suppressed |
| Tradjenta | Linagliptin | 68 | suppressed |
| Glipizide Er | Glipizide | 67 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 65 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 65 | 11 |
| Carbamazepine Er | Carbamazepine | 64 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 64 | 30 |
| Linzess | Linaclotide | 64 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 64 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 64 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 62 | suppressed |
| Scopolamine | Scopolamine | 62 | suppressed |
| Verapamil Er | Verapamil Hcl | 62 | suppressed |
| Insulin Lispro | Insulin Lispro | 61 | 16 |
| Memantine Hcl Er | Memantine Hcl | 61 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 61 | 20 |
| Ranolazine Er | Ranolazine | 61 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 60 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | suppressed |
| Fenofibrate | Fenofibrate | 58 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 57 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 46 |
| Temazepam | Temazepam | 56 | 17 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 54 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 53 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 53 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 53 | suppressed |
| Ramelteon | Ramelteon | 53 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 52 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 52 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 52 | 28 |
| Rytary | Carbidopa/Levodopa | 52 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 51 | suppressed |
| Trulicity | Dulaglutide | 51 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 11 |
| Methimazole | Methimazole | 46 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 45 | suppressed |
| Dutasteride | Dutasteride | 44 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 17 |
| Amoxicillin | Amoxicillin | 42 | 28 |
| Sevelamer Hcl | Sevelamer Hcl | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 35 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 41 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 13 |
| Primidone | Primidone | 39 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 39 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | 12 |
| Cephalexin | Cephalexin | 37 | suppressed |
| Lacosamide | Lacosamide | 37 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 37 | 13 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 37 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 36 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 36 | suppressed |
| Carbamazepine | Carbamazepine | 35 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 35 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 16 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Paliperidone Er | Paliperidone | 31 | suppressed |
| Austedo | Deutetrabenazine | 30 | suppressed |
| Rivastigmine | Rivastigmine | 30 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 14 |
| Phenytek | Phenytoin Sodium Extended | 27 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 25 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 11 |
| Lactulose | Lactulose | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 23 | 12 |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 15 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 16 |
| Valsartan | Valsartan | 22 | suppressed |
| Anastrozole | Anastrozole | 21 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Levemir | Insulin Detemir | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Loxapine | Loxapine Succinate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 17 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Desloratadine | Desloratadine | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Bicalutamide | Bicalutamide | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Brilinta | Ticagrelor | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Permethrin | Permethrin | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Insulin Aspart | Insulin Aspart | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Pimecrolimus | Pimecrolimus | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,176.17 · 90 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, APRETUDE, AUSTEDO XR, Auvelity, BREZTRI, CAMZYOS, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EPIDIOLEX, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, HETLIOZ, INGREZZA, JARDIANCE, Kerendia, Korlym, LINZESS, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TZIELD, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZORYVE | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error